How Long to Stay on 2.5mg Mounjaro — and When to Move Up

2.5mg is a starter dose, not a therapeutic weight-loss dose, its job is to let your body adjust to tirzepatide before the dose rises.
The licensed schedule sets the 2.5mg period at four weeks; staying longer is sometimes appropriate but requires a prescriber's decision.
Moving up before four weeks, or skipping the starter phase entirely, is not supported by the prescribing guidance in the Mounjaro SmPC.
Every dose change at nume is reviewed by a GPhC-registered Independent Prescriber, your next pen is only issued after that clinical sign-off.

Most people stay on the 2.5mg Mounjaro dose for exactly four weeks. That single month is built into the licensed schedule as a tolerance-settling period, not a treatment phase — your prescriber will assess whether you're ready to move to 5mg once it's done. These are prescription-only decisions: tirzepatide is a POM, and the timing of any dose change requires clinical review. More on how Mounjaro works if you want the broader picture first.

Starting from £29.99/mo

Free 2-minute consultation · Reviewed same day

Start journey
The nume Promise

Order by 12pm.

At your door the next working day.
Free, tracked, plain packaging.

Guaranteed on approved orders

Where are you starting from?

BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.

Check your BMI.

Ten seconds. Private — nothing is stored or shared.

80 kg
170 cm

Your result updates live in the card alongside.

Your result

Your BMI is

which is in the healthy weight range

Start journey

BMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.

Treatment options

Weight loss treatments

The problem

Most weight loss services treat you like a transaction, a checkout, a courier, and you're on your own.

Algorithm approvalsNo real clinicianGeneric dosingHidden feesSlow deliverySilence after checkout

The nume way

We built the opposite: one clinician who knows you, guaranteed care at every step.

24 hrs

clinician review. Free next working day delivery.

How it works

From consultation to your door, properly.

Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.

Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.

Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.

The four-week starter phase: what it does, what happens next, and when a longer stay makes clinical sense

Step 1, Why the 2.5mg period exists (and what it isn't)

The Mounjaro prescribing schedule, as set out in the Mounjaro SmPC on the eMC, begins at 2.5mg for one reason that isn't obvious from the dose number itself: your digestive system needs time to adapt to a dual GIP and GLP-1 receptor agonist. Tirzepatide slows gastric emptying and changes the hormonal signals your gut sends around mealtimes. Do that too fast, and nausea, vomiting and stomach discomfort become very likely. The 2.5mg period dampens that response while your system catches up.

This is worth saying plainly: 2.5mg is not where the meaningful weight change happens for most people. The clinical trial data across the SURMOUNT programme showed weight reductions building at higher maintenance doses. At 2.5mg, the dose is doing groundwork. People sometimes worry when the scales barely move in week two or three, that's by design, not a sign the medicine isn't working.

The standard duration is four weeks, and if you want a fuller picture of how long you typically stay on 2.5mg Mounjaro and what shapes that timeline, our dedicated page covers it in detail. Many prescribers will tell you that patients who push to skip ahead tend to have a rougher time with side effects at 5mg, precisely because they cut the settling period short.

Step 2, What your prescriber checks before moving you to 5mg

After four weeks on 2.5mg, a clinical review determines whether to increase. At nume, a real prescriber reads your update (not a decision tree) before your next pen is issued. The things being considered aren't complicated, but they matter: how well you tolerated the starter dose, whether any side effects are still active and settling or have resolved, your current weight relative to baseline, and any relevant changes to your health or medicines.

If you've sailed through four weeks with minimal nausea and no ongoing issues, moving to 5mg is generally straightforward. If you've had a difficult patch (persistent nausea, significant vomiting, or you started at an unusually sensitive point in your health) your prescriber might recommend staying at 2.5mg for another four weeks before stepping up. That's a legitimate clinical call, not a delay for its own sake. Our clinical team takes this review seriously because the dose increase to 5mg is where most people first feel tirzepatide's appetite effects clearly.

One practical note: your treatment arrives via DPD in plain, unbranded packaging, and your tracking link will show exactly when the next pen is on its way, useful to know, since the review and dispatch timelines align.

Step 3, When staying on 2.5mg longer than four weeks is the right call

There are genuine situations where a prescriber decides that extending the 2.5mg period is better than pushing ahead. These include persistent GI side effects that haven't settled by week four, a recent illness that made the first month harder to read accurately, or certain other medicines being taken alongside tirzepatide that the prescriber wants to monitor before adding dose intensity.

If you're curious whether staying at 2.5mg longer is appropriate in your specific circumstances, the question of whether remaining at 2.5mg is clinically reasonable is one our prescribers field regularly. The short answer is that extended time at the starter dose isn't wrong in itself; it simply delays the dose at which tirzepatide becomes most effective for weight management. Nobody should feel rushed, but the decision should be driven by clinical reasoning, not uncertainty about the schedule.

The NHS tirzepatide page describes the general titration approach and is worth reading alongside the patient information leaflet that comes with your pen. Always refer to that leaflet (and your prescriber) for guidance specific to your dose and circumstances, rather than any general summary including this one.

What this means for the rest of the schedule

Once you move off 2.5mg, the next stage is 5mg for another four weeks, then the titration continues through 7.5mg, 10mg, 12.5mg and up to 15mg if clinically appropriate and tolerated. Most people don't need to reach 15mg, and some find a lower maintenance dose works well for them. The 5mg stage has its own distinct questions worth knowing before you get there.

The cost structure of private treatment is worth understanding as you plan ahead; this breakdown of Mounjaro pricing in the UK explains what legitimate treatment involves across the dose range. And if you've ever wondered what the upper end of the schedule looks like, the 15mg guidance page covers that territory.

Thinking about starting? Eligibility for a private prescription doesn't require a GP referral or a waiting list. A free consultation with our prescribers is the first step, reviewed the same day, with clinical suitability confirmed before anything is prescribed.

Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.
Start free consultation

The people

Meet the team.

Mahommed Zunaid Ayub Patel

Superintendent Pharmacist (GPhC No. 2217101)

Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.

Mostafa Damghani

Clinical Lead (GPhC No. 2231744)

Sets our clinical standards and checks everything we publish against current MHRA guidance.

Shelan Salih

Independent Prescriber (GPhC No. 2084501)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Rehenaaz Uddin

Independent Prescriber (GPhC No. 2083426)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Frequently asked questions